

**Supplementary Table 1.** Tumor properties from asymptomatic adult Mut3 or Mut4 mice used for MRI

Genotype	ID	Age (weeks) <sup>a</sup>	Tumor volume <sup>b</sup>		Growth per week (%)	Grade	Ki67 density (%) <sup>c</sup>	
			1 <sup>st</sup> scan	2 <sup>nd</sup> scan				
Mut3 (n = 3)	8495	26.7	0.051 (1/05)	0.060 (1/13)	15.44	3	21.9	
	9042	25.3	0.027 (2/16)	0.029 (2/23)	7.41	3	12.1	
	11714	22.7	0.045 (8/10)	0.065 (8/17)	44.44	3	31.4	
	mean	24.9		0.051	22.43 ± 11.25 <sup>d</sup>		21.8 ± 5.6 <sup>d</sup>	
	8625	21.6					Excluded; no tumor detection for 3 weeks	
	9044	27.3	0.002 (2/23)	0.0022 (3/2)	10.00		Excluded; too small tumor at 1 <sup>st</sup> scanning <sup>e</sup>	
	11415	26.3					Excluded; no tumor detection for 2 weeks	
	11685	23.4					Excluded; no tumor detection for 2 weeks	
	Mut4 (n = 6)	8985	17.9	0.014 (12/12)	0.031 (12/19)	121.43	3	47.5
		9505	13.1	0.023 (12/27)	0.042 (1/5)	42.03	3	30.3
9660		14.1	0.031 (1/13)	0.058 (1/20)	87.10	3	37.4	
10590		17.1	0.041 (4/13)	0.073 (4/20)	78.05	3	35.7	
10594		14.1	0.012 (3/23)	0.021 (3/30)	75.00	3	39.6	
12130		18.0	0.029 (8/10)	0.085 (8/17)	193.10	3	67.8	
mean		15.7		0.052	99.45 ± 23.46 <sup>d</sup>		43.1 ± 5.5 <sup>d</sup>	
9075		16.3					Excluded; death during 1 <sup>st</sup> scanning	
9573		14.1	0.013 (1/5)				Excluded; death during 1 <sup>st</sup> scanning	
10448		11.4					Excluded; no tumor detection for 6 weeks	
10592	17.1	0.006 (4/13)	0.032 (4/20)	433.33		Excluded; too small tumor at 1 <sup>st</sup> scanning <sup>e</sup>		
10589	14.1	0.032 (3/23)				Excluded; death before 2 <sup>nd</sup> scanning		

<sup>a</sup>Age at the first scan<sup>b</sup>Tumor volume in cm<sup>3</sup> (date of scanning)<sup>c</sup>Ki67 density = the highest ratio of Ki67-positive cells / total cells (DAPI-positive) in a 0.44 X 0.35 mm<sup>2</sup> field<sup>d</sup>Mean ± standard error mean<sup>e</sup>Tumors with volume smaller than 0.01 cm<sup>3</sup> at the 1<sup>st</sup> scan were excluded to compare tumors at a similar stage and size.

**Supplementary Table 2.** Sequence of PCR primers used to measure LOH of Nf1 and Pten

PCR for	Name	Sequence	Product size (bp)
<i>Nf1</i> <sup>f</sup>	g54	5'-AATGT GAAAT TGGTG TCGAG TAAGG TAACC AC-3'	<i>wt</i> : 493
	g35	5'-TTAAG AGCAT CTGCT GCTCT TAGAG GGAA-3'	<i>loxP</i> : ~600
	g53	5'-TCAGA CTGAT TGTTG TACCT GATGG TTGTA CC-3'	$\Delta$ <i>loxP</i> : ~300
<i>Pten</i> <sup>f</sup>	F2	5'-CCATC ACACT AAGGT CTGTG G-3'	<i>wt</i> : 135
	R	5'-ACTCC CACCA ATGAA CAAAC-3'	<i>loxP</i> : 346
	hD1	5'-CCAGT AGTGA TAGAA CGGAA GTC-3'	$\Delta$ <i>loxP</i> : 410

**Supplementary Table 3.** Grade and location of malignant astrocytomas found in symptomatic Mut3, Mut4 or Mut6 mice

Genotype	ID	Age (weeks)	Grade	Location of tumor
Mut3 (n = 11)	1512	27.0	3	Thalamus/pons/Mb
	2214	32.6	3	Most forebrain including SVZ
	2512	13.0	4	Most forebrain including SVZ
	2897	28.4	3	Most forebrain including SVZ
	2898	26.0	3	Thalamus/pons
	3853	31.0	3	St/SVZ/BS
	5780	44.0	4	St/RMS/OB
	6634	33.6	3	Cx, SVZ, BS
	6953	28.4	3	Most forebrain including SVZ
	8495	27.9	3	St/RMS
	14047	16.7	4	St/RMS/SVZ/Thalamus/Ht
Mut4 (n = 10)	652	25.7	3	Pons/Cb
	749	16.7	4	Most forebrain including SVZ
	2244	13.1	3	CC/St
	2247	14.1	3	Cx/CC, thalamus
	2735	14.9	3	Most forebrain including SVZ
	2737	22.3	4	RMS/St/CC/SVZ, Hp, BS
	2901	28.4	3	Most brain, except Cb
	2909	17.4	3	Most forebrain including SVZ
	4025	17.3	3	OB
	5895	20.0	3	St/SVZ/thalamus
Mut5 (n = 6)	4567	23.4	4	St, caudal CC, Cb
	11719	20.0	3	OB
	11724	22.7	3	St/SVZ
	11908	22.4	4	CC/SVZ/DG
	11995	26.6	4	St/SVZ/Thalamus
	12365	20.0	4	Thalamus/Ht
Mut6 (n = 8)	5142	14.4	4	Caudal CC/Mb/Ht
	5239	14.1	4	CC/Cx, BS
	5245	12.9	4	Pons/Mb
	5586	14.3	4	Most forebrain including SVZ
	8214	18.3	4	St, Caudal CC/Mb/Cb
	8227	16.7	4	Most forebrain including SVZ
	10427	17.9	4	St/SVZ/thalamus
	10897	10.7	3	St, Cb

BS, brain stem; CC, corpus callosum; Cb, cerebellum; Cx, cerebral cortex; DG, dentate gyrus; Hp, hippocampus; Ht, hypothalamus; Mb, midbrain; OB, olfactory bulb; RMS, rostral migratory stream; St, striatum; SVZ, subventricular zone

**Supplementary Table 4.** BrdU signals detected in the vicinity of the SVZ/RMS of 7-week-old mice one week after labeling


Genotype	Mouse ID	Number of BrdU-positive cells <sup>a</sup>		
		r. CC <sup>b</sup>	r. St <sup>c</sup>	c. St <sup>d</sup>
Control:	12572	27	3	4
<i>p53</i> <sup>+/-</sup> (n = 6)	12574	26	6	7
	12578	10	6	4
	15357	32	5	6
	15360	9	5	5
	15512	21	4	4
	average		20.8 ± 9.5 <sup>e</sup>	4.8 ± 1.2
<i>cre; Pten</i> <sup>f/+</sup> (n = 2)	9224	22	7	8
	15548	25	6	1
Mut3 (n = 2)	15374	25	7	2
	15377	7	8	8
Mut4 (n = 3)	15510	24	2	3
	<b>15511<sup>f</sup></b>	<b>56</b>	<b>119</b>	<b>38</b>
	15546	16	6	6
Mut5 (n = 3)	12573	32	8	6
	12575	11	8	7
	12579	24	9	8
Mut6 (n = 3)	<b>9219</b>	<b>59</b>	9	<b>14</b>
	<b>9220</b>	<b>57</b>	<b>30</b>	9
	<b>9221</b>	37	<b>32</b>	<b>28</b>

<sup>a</sup>Anatomically matched sections were stained with BrdU antibody and subsequently visualized by Alexa-488-conjugated anti-mouse IgG antibody. BrdU-positive cells in below regions in a 0.87 X 0.69 mm<sup>2</sup> area were counted.

<sup>b</sup>Rostral corpus callosum

<sup>c</sup>Rostral striatum

<sup>d</sup>Caudal striatum



<sup>e</sup>Mean ± standard deviation

<sup>f</sup>Mouse IDs and abnormally increased BrdU counting (more than twice of average of control) were highlighted by a bold font.